Locations:
Search IconSearch
April 4, 2018/Cancer/News & Insight

Social Media and Journal Clubs: The Ultimate Peer Review?

An oncologist weighs in

social-media_650x450

ByAaron Gerds, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The Cotton Club, The Breakfast Club and journal club. Like other legendary clubs, journal club has centered around an in-person gathering to facilitate the exchange of commentary and ideas on a given topic. The critical evaluation of recent articles conducted in journal clubs serves as a building block for medical education, evidence-based guidelines and quality improvement initiatives. From residency training, I have very vivid — dare I say fond? — memories of journal club at Hines VA Hospital getting into the nitty gritty of numbers needed to treat with then Chairman Brian Schmitt, MD, MPH. For the past 180 years, from Sir James Paget to Gordon Guyatt, MD, MSc, journal clubs have been steadfast with a very gradual evolution, but the technology revolution is shaking things up.

Social media, including Twitter, has changed the way we communicate. In addition to focused composition and the introduction of emoji, it has also eliminated distance and time. Discussions including thousands can be had instantly across the globe. It has been argued that social media has dumbed down discourse, reducing it to a series of likes or retweets. Despite its limitations, it can be a powerful tool in the appraisal of the medical literature.

With most manuscripts posted on publishers’ websites well in advance of print, the peer review process can occur almost instantaneously. Social media also enables the readership to interact directly with the authors.

With such a large volume of users, critiques presented and validated are essentially crowdsourced, and conversely, individuals can provide insight on how local context may affect the application of results in their own practice. Social media invites its users to come off the bench and get into the game, identifying quality and refuting misinterpretation by a simple post for many, with others taking the next step into content creation. One key element yet to be clarified as things move forward is how these contributions will be measured and how faculty will get academic credit for participating in online forums.

Advertisement

While time will tell if Twitter and social media are the ultimate peer review, it is clear that they can be a powerful tool in conducting academic medicine. I wonder if William Osler would share his critiques in 280 characters or less.

Dr. Gerds is a staff physician in the Department of Hematology and Medical Oncology and publishes in medical literature about social media use. Follow him on Twitter @AaronGerds.

Advertisement

Related Articles

Surgeon
June 30, 2025/Cancer/News & Insight
Potential for Deintensification of Surgical Interventions in Low-Risk Breast Cancer

Reconsidering axillary lymph node dissection as well as depth of surgical margins

Dendritic cell
June 26, 2025/Cancer/News & Insight
Avelumab Induces Natural Killer Cell Activation and Dendritic Cell Crosstalk

Researchers uncover profound differences in the mechanism of action between different PD-L1 checkpoint inhibitors

World map
June 19, 2025/Cancer/News & Insight
Breaking Barriers to Cancer Care: Cleveland Clinic’s Global Approach

A multi-pronged strategy for tackling cancer access problems

CAR T-cell therapy illustration
June 12, 2025/Cancer/News & Insight
First-Ever U.S. Trial of CAR T-Cell Therapy for Relapsed/Refractory AL Amyloidosis

Early results show patients experiencing deep and complete response

scan showing cholangiocarcinoma
June 5, 2025/Cancer/News & Insight
Exploring Novel Therapeutic Avenues in Advanced Cholangiocarcinoma: Lessons from the EA2187 Trial

Collaborative research effort underscores the urgent need for effective second-line therapies in this rare, aggressive cancer

Anticoagulant sign
June 4, 2025/Cancer/News & Insight
Direct-Acting Oral Anticoagulants Safe for Patients with Brain Metastasis

Largest study to date comparing direct-acting oral anticoagulants to low-molecular-weight heparin

Squamous cell carcinoma
June 2, 2025/Cancer/News & Insight
Adjuvant Immunotherapy in High-Risk Cutaneous Squamous Cell Carcinoma

Pembrolizumab does not improve outcomes, but immunotherapy may still offer benefit

Ad